April 25, 2016 — Sanofi-Aventis is accused of failing to warn about the risk of permanent hair loss from Taxotere (docetaxel) in a federal lawsuit that was filed by a breast cancer patient in Colorado.
The lawsuit (PDF) was filed by Melissa F. Leith on March 30 in the U.S. District Court for Colorado (Case No. 1:16-cv-00714).
In September 2012, Leith was diagnosed with breast cancer and met with her oncologist to discuss treatment options. She chose chemotherapy that included Taxotere, but says she was never warned about the risk of permanent hair loss. After undergoing treatment between February and April 2013, she developed disfiguring permanent alopecia.
A growing number of lawsuits accuse Sanofi-Aventis of downplaying the risk of long-term baldness to protect sales of Taxotere. According to the complaint:
“Defendants obtained billions of dollars in increased revenues at the expense of unwary cancer victims simply hoping to survive their condition and return to a normal life.”
Permanent alopecia was not added to the label on Taxotere in the United States until December 2015. However, labels in Europe and Canada were updated in 2005 and 2012, respectively.
In 2005, Sanofi-Aventis received results from GEICAM 9805, a large clinical trial investigating Taxotere in breast cancer patients as part of the TAC regimen (Taxotere, Adriamycin, and Cyclophosphamide). At the end of the 10-year follow-up period, 9.2% of patients (49 women) who were given Taxtoere had permanent hair loss.
Do I have a Taxotere Lawsuit?
The Schmidt Firm, PLLC is currently accepting Taxotere induced injury cases in all 50 states. If you or somebody you know has been diagnosed with permanent hair loss, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Drug Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.